1. Introduction {#s0005}
===============

Coronavirus disease 2019 (COVID-19) caused by the infection with a novel coronavirus (NCoV-19), also known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is rapidly spreading through the globe. This emerging world-wide pandemic is taking its toll in a form of heavy morbidity and mortality (SARS-CoV-2 is more transmissible and lethal than influenza) and has large scale socio-economic impact ([@bb0740]). It seems that COVID-19, which was originally reported at the end of December 2019 as a "pneumonia of unknown etiology" in four patients in Wuhan, Hubei Province, China, is now present at each and any corner of the world. Although COVID-19 is characterized by rather mild symptoms of a typical respiratory illness that include fever, cough, sore throat, shortness of breath, as well as mild gastrointestinal (GI) symptoms in some patients, there are also multiple more serious cases, where the infection is causing severe pneumonia and even death, with an increase in risk of mortality of COVID-19 pneumonia being associated with age ≥ 65 years and preexisting concurrent cardiovascular or cerebrovascular diseases ([@bb0160]). In light of the current COVID-19 outbreak, everyone is guessing what makes SARS-CoV-2 so special.

Although coronaviruses (CoVs) are widespread among vertebrates, they often cause only mild respiratory or enteric infections ([@bb0475]). CoVs belong to the subfamily *Coronavirinae* of the *Coronaviridae* family (which also includes the *Torovirinae* subfamily) in the order *Nidovirales* (<http://ictvonline.org/virusTaxonomy.asp?version=2012>). They are divided into four genera, namely α-, β-, γ-, and δ-CoVs, with β-CoVs being further separated into clades a--d ([@bb0105]). α- and β-CoV are able to infect mammals (including humans and domestic animals), while γ- and δ-CoV tend to infect birds. Six CoVs have previously been identified as human-infecting viruses, among which are two α-CoVs, HCoV-229E and HCoV-NL63, and two β-CoVs, HCoV-HKU1 and HCoV-OC43 characterized by low pathogenicity and typically causing mild respiratory symptoms similar to a common cold. The other two known human β-CoVs, Severe Acute Respiratory Syndrome CoV (SARS-CoV) and Middle East Respiratory Syndrome CoV (MERS-CoV), lead to severe and potentially fatal respiratory tract infections and because of that have received special attention as emergent pathogens in humans, with the potential to create global epidemics ([@bb0745]). The emergence of human-infecting CoVs is likely associated with the cross-species transmission events ([@bb0155]).

There is now a new player on the block, a novel coronavirus (NCoV-19), also known as SARS-CoV-2, which is another emerging pathogen currently representing a global threat. The genetic sequence analysis demonstrated that SARS-CoV-2 belongs to the β-coronavirus genera. This enveloped non-segmented positive-sense RNA virus (subgenus Sarbecovirus, *Orthocoronavirinae* subfamily) shows 79.5% nucleotide identity to SARS-CoV and 52% identity to MERS-CoV ([@bb0260]; [@bb0775]). Despite this similarity, SARS-CoV-2 shows higher levels of infectivity than the SARS-CoV and MERS-CoV did. At the moment, SARS-CoV-2 is showing a rapid worldwide spread, ever increasing morbidity and mortality rates. As a result of this rapid spread of SARS-CoV-2 infection, the WHO designated the SARS-CoV-2 infection disease (COVID-19) as a Public Health Emergency of International Concern on 30 January 2020, and subsequently, on March 11, 2020, declared it a Global Pandemic. It is impossible to provide here an accurate evaluation of the COVID-19-associated morbidity and mortality, since the corresponding numbers are changing on the hourly basis. Although COVID-19 is typically characterized by the symptoms of viral pneumonia, many COVID-19 patients are dying because of a complex organ failure ([@bb0165]; [@bb0755]). Older patients, especially those who have underlying illness, such as cardiovascular disease, liver disease, kidney disease or malignant tumors can become severely ill ([@bb0060]; [@bb0305]; [@bb0670]; [@bb0680]).

Clinical course of COVID-19 is characterized according to the Chinese Clinical Guidance for the COVID-19 Pneumonia Diagnosis and Treatment (7th edition) ([@bb0090]). Incubation period for COVID-19 ranges from 1 to 14 days. The first and main symptoms are nonspecific fever that can be mild to moderate or even absent in some patients, fatigue, and dry cough, which may become associated with respiratory symptoms, such as nasal obstruction, runny nose, and sore throat, myalgia or diarrhea. The condition may progress to become severe within one week of onset to present by dyspnea and/or hypoxia. Some patients deteriorate to ARDS, septic shock, refractory metabolic acidosis, coagulation dysfunction, and multiple organ system failure leading to death (see Supplementary Materials, Table S1).

The renin-angiotensin-aldosterone system (RAAS, also known as renin--angiotensin system, RAS) is a hormone system responsible for the regulation of blood pressure and fluid and electrolyte balance, and for the control of the systemic vascular resistance. RAAS includes a cascade of vasoactive peptides that coordinates key processes in human physiology. Angiotensin-converting enzyme 2 (ACE2), an enzyme that physiologically inhibits RAAS activation, functions as a receptor for both SARS-CoV and SARS-CoV-2, which have been responsible for the SARS epidemic in 2002 to 2004 and for the more recent COVID-19 pandemic, respectively ([@bb0235]; [@bb0290]; [@bb0370]; [@bb0675]; [@bb0735]).

2. The renin-angiotensin-aldosterone system and its inhibitors {#s0010}
==============================================================

Juxtaglomerular (JG) cells within the afferent arterioles of the kidney secrete prorenin in its inactive form. Activation of JG cells by decreased blood pressure, or decreased sodium load in the distal convoluted tubule or via β-activation causes the cleavage of prorenin to produce mature renin ([@bb0445]; [@bb0510]). Once released, renin acts on its target, angiotensinogen, produced by the liver, converting it into angiotensin I. Angiotensin I (a decapeptide) is physiologically inactive, but serves as a precursor for angiotensin II (an octapeptide). Angiotensin converting enzyme-1 (ACE1) converts angiotensin I to angiotensin II that acts as an agonist for both angiotensin II receptors type 1 and type 2 (AT~1~R and AT~2~R, respectively). Angiotensin II is converted, by ACE2, to the heptapeptide angiotensin-(1--7). ACE2 also converts angiotensin I to the nonapeptide angiotensin-(1--9), which is further processed by ACE1 to generate angiotensin-(1--7) that serves as an antagonist for the AT~1~R receptors and an agonist for the MAS1 receptor (MasR, also known as proto-oncogene Mas).

SARS-CoV-2 infection down-regulates ACE2 expression with subsequent elevation of plasma angiotensin II levels, which are in turn correlate with the total viral load and the degree of lung injury ([@bb0265]). Curiously, a recent study performed by Ziegler *et al*. demonstrated that human *ACE2* is an interferon-stimulated gene (ISG) and that interferon is capable of induction of broader expression of ACE2 in upper airway epithelial cells, suggesting that SARS-CoV-2 can utilize such interferon-driven upregulation of ACE2 to further enhance infection ([@bb0780]).

ACE1 inhibitors inhibit the conversion of angiotensin I to angiotensin II and angiotensin-(1--9) transformation to angiotensin-(1--7), thereby attenuating angiotensin II vasoconstriction, sodium retention, proinflammatory, and profibrogenic effects. Inhibitors of ACE2 have been developed, but none has been marketed as of yet. Angiotensin receptor blockers (ARBs) inhibit the actions of angiotensin II and angiotensin-(1--7) on the angiotensin AT~1~Rs. Therefore, ACE2 serves as a key enzyme for the balance between the two main arms of the RAAS: the classic RAAS, which is the ACE1/angiotensin II/ angiotensin II type 1 receptor axis the anti-RAS, which is the ACE2/angiotensin-(1--7)/Mas receptor (MasR) axis ([@bb0525]).

Finally, the alamandine pathway should be mentioned here ([@bb0525]). This pathway is based on the ability of ACE2 to interacts with the other group of the angiotensin peptides, alatensins, in which the N-terminal aspartate is replaced by alanine, leading to Ala-angiotensin-(1--7) (known as alamandine) capable of binding to the Mas-related G protein-coupled receptor D (MrgD) ([@bb0520]). The effects of the alamandine interaction with MrgD are similar to the effects of the angiotensin-(1--7) stimulating MasR ([@bb0525]). Therefore, the SARS-CoV-2-induced downregulation of ACE2 leads to a consequent changes in the levels of both angiotensin-(1--7) and alamandine ([@bb0525]).

3. Entry of SARS-CoV-2 into cells {#s0015}
=================================

SARS-CoV-2 uses the SARS-CoV receptor ACE2 (expressed in the principal target cells for SARS-CoV-2, such as the heart, kidneys, intestine, and lung alveolar epithelial cells,) for entry and the transmembrane protease, serine 2 (TMPRSS2, also known as serine protease 10) for the spike (S) glycoprotein priming ([@bb0290]). The S glycoproteins of coronaviruses have two subunits, S1, and S2. The S1 subunit binds to the ACE2 enzyme, via its RBD, on the cell membrane and S2, fuses with the cell membrane ([@bb0345]). In addition, S protein priming by cellular proteases is needed for viral entry, which can proceed in two ways. (a) A host [TMPRSS2](https://pubmed.ncbi.nlm.nih.gov/24227843){#ir0100} activates the S and cleaves ACE2; (b) TMPRSS2 causes irreversible conformational changes in the S2 subunits, activating them, and facilitating fusion of the virus to the cell membrane. The virus then enters the cell ([@bb0240]; [@bb0285]). According to Hoffmann *et al*., ACE2 and TMPRSS2 are essential in airway cells for SARS-CoV-2 infection. A serine protease inhibitor, Camostat mesylate, used in Japan to treat [chronic pancreatitis](https://pubmed.ncbi.nlm.nih.gov/31412955){#ir0105}, inhibits the TMPRSS2 and partially [blocks the entry of SARS-CoV-2](https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2421){#ir0110} into bronchial epithelial cells *in vitro* ([@bb0290]).

The efficient COVID-19 transmission from human to human within the population may be explained by the \~10--20 fold higher affinity of the SARS-CoV-2 spike protein to the human angiotensin-converting enzyme-2 (ACE2) than the corresponding affinity of the SARS-CoV spike protein ([@bb0705]). It is also speculated that the presence of a unique furin cleavage site within the SARS-CoV-2 spike protein, which is a novel feature setting this virus apart from SARS-CoV, and the almost ubiquitous expression of furin-like proteases could participate in expanding SARS-CoV-2 cell and tissue tropism, relative to SARS-CoV, as well as increasing its transmissibility and/or altering its pathogenicity ([@bb0065]; [@bb0660]; [@bb0705]; [@bb0730]). In the same line, the distinctive structural differences between the receptor-binding domains (RBDs) of the spike proteins from SARS-CoV and SARS-CoV-2 can represent energetically favorable changes for the more efficient interaction of the SARS-CoV-2 spike protein with the ACE2 receptor. In fact, the local environment present in the ACE2 receptor allows these mutations to produce a significant number of electrostatic stabilizing interactions. Furthermore, the presence of the two capping loops in the RBD of the SARS-CoV-2 spike protein is likely to produce a more stabilization effect over the interaction with the cellular receptor. These two loops around the RBD of SARS-CoV-2 might be promoting the interaction with the ACE2 receptor, improving the binding to the ACE2 by increasing the number of atoms involved. Therefore, the amino acid substitutions and the longer capping loops could explain the increase in the binding affinities in SARS-CoV-2 compared to SARS-CoV. Higher affinity values might be related to the dynamics of the infection and the rapid spread observed for this virus ([@bb0465]). Wan *et al*., based on their computational analysis, suggested that when all the human-ACE2-favoring residues were combined into one RBD, this RBD would bind to human ACE2 with super affinity and the corresponding spike protein would mediate viral entry into human cells with super efficiency, which may improve the epidemic surveillance ([@bb0665]) and the virus virulence.

Viral entry and lung type II pneumocytes infection triggers an inflammatory cascade in the lower respiratory tract. This inflammatory cascade is initiated by the antigen-presenting cells (APC) performing two functions, (i) presenting the foreign antigen to CD~4~ ^+^-T-helper (Th1) cells, and (ii) releasing interleukin-12 to further stimulate the Th1 cell. The Th1 cells stimulate CD~8~ ^+^-T-killer cells that will target any cells containing the foreign antigen. In addition, activated Th1 cells stimulate B-cells to produce antigen-specific antibodies ([@bb0350]; [@bb0505]).

The antibody profile against SARS-CoV virus has a typical pattern of IgM and IgG production. The SARS-specific IgM antibodies disappear at the end of week 12, while the IgG antibody can last for a long time, indicating that IgG antibody may mainly play a protective role ([@bb0365]). The latest report shows the number of CD~4~ ^+^ and CD~8~ ^+^ T cells in the peripheral blood of SARS-CoV-2-infected patients is significantly reduced. However, these cells are excessively activated, as evidenced by high proportions of HLA-DR (CD4 3.47%) and CD38 (CD8 39.4%) double-positive fractions ([@bb0720]). These T-cell responses can inhibit the over activation of innate immunity and clear SARS-CoV-2.

However, uncontrolled systemic inflammatory response resulting from the release of large amounts of pro-inflammatory cytokines (such as IFN-α, IFN-γ, IL-1β, IL-6, IL-12, IL-18, IL-33, TNF-α, TGFβ, etc.) and chemokines (CCL2, CCL3, CCL5, CXCL8, CXCL9, CXCL10, etc.) by immune effector cells results in the cytokine storm ([@bb0425]), which, with a suboptimal T-cell response, triggers diffuse alveolar damage with marked pulmonary edema and hyaline membrane formation, causing acute respiratory distress syndrome (ARDS). ARDS is the main cause of death in severe cases of SARS-CoV-2 infection, just like what occurred in SARS-CoV and MERS-CoV infection ([@bb0720]).

SARS-CoV-2 virus as one of respiratory viruses normally attach to receptors on the cellular airways with a low level of viraemia detected in some symptomatic patients. Viraemia was detected in six of 41 patients (15%) in China ([@bb0305]), but only in one of 12 patients (8%) in the study from Singapore ([@bb0750]). Another study from China, reported only three PCR-positive samples (1%) out of 307 blood samples ([@bb0685]). The results of PCR testing of serum samples in six viraemic patients suggested a very low viral load in specimens ([@bb0305]). Yet, multiple organ involvement including the heart, kidney, liver, and gastrointestinal tract have been recently reported in patients with COVID-19 ([@bb0060]).

The action mechanism a COVID-19 infection on the kidney is likely to be multifactorial; (a) SARS-CoV-2 may exert direct cytopathic effects on kidney tissue by entering through an ACE2- related signaling pathways. This is supported by the detection of SARS-CoV-2 genomic fragments in blood and urine of patients with COVID-19 ([@bb0305]); (b) Virus-induced cytokines or mediators might exert indirect effects on renal tissue, such as hypoxia, shock, and rhabdomyolysis ([@bb0075]); (c) Deposition of immune complexes of viral antigen may damage the kidney. However, kidney microscopy specimens from patients with SARS showed a normal glomerular aspect and absence of electron-dense deposits ([@bb0080]). The etiology of acute myocardial injury caused by SARS-CoV-2 infection might be related to the ACE2-dependent pathway or the cytokine storm, respiratory dysfunction, and hypoxaemia ([@bb0100]; [@bb0580]; [@bb0765]).

4. Effects of angiotensin converting enzyme-1 inhibitors {#s0020}
========================================================

Treatment with agents, which have an impact on the RAAS as ACE inhibitors (ACEi) or ARBs is common in patients with hypertension, cardiac diseases and diabetes. In humans, the effects of RAAS inhibition on ACE2 expression were studied a little. Administration of ACE inhibitors in patients with coronary artery disease and hypertension did not affect angiotensin-(1--7) production, questioning its effect on ACE2 ([@bb0045]; [@bb0390]). In other studies, it was found to up-regulate ACE2 receptor expression ([@bb0265]; [@bb0655]). Data showing the effects of ACE inhibitors, ARBs, and other RAAS inhibitors on lung-specific expression of ACE2 in experimental animal models and in humans are lacking ([@bb0645]). It is not clear whether such up regulation of ACE2 would be desirable or not. Theoretically, increased ACE2 activity could increase ability of SARS-CoV-2 to penetrate cells being its receptor. In contrast, increased production of angiotensin-(1--7) from angiotensin II under the action of ACE2 could lead to increased anti-inflammatory activity and some [protection from the lung damage](https://pubmed.ncbi.nlm.nih.gov/16007097){#ir0115} caused by the virus ([@bb0100]).

There is no sufficient experimental or clinical data demonstrating the beneficial or adverse outcomes of the background use of ACE1, ARBs or other RAAS antagonists in COVID-19 or among COVID-19 patients with a history of cardiovascular disease treated with such agents. However, severe COVID-19 forms were described in patients with hypertension and diabetes mellitus; i.e., conditions known to be associated with RAAS blockade therapy ([@bb0250]), suggesting that patients on ACE inhibitors or ARB could be at a greater risk due to the mechanism by which SARS-CoV-2 enters the cell ([@bb0035]). One should keep in mind though that the generality of this hypothesis could be questionable. In fact, although no randomized controlled trials are still available, several observational studies of good quality have been recently published, all denying the hypothesis that patients taking ACE inhibitors or ARB could be at a greater risk of SARS-CoV-2 infection or development of the severe COVID-19 forms ([@bb0255]; [@bb0315]; [@bb0405]). Accordingly, the Council on Hypertension of the European Society of Cardiology, the American College of Cardiology, American Heart Association, and Heart Failure Society of America strongly recommend that physicians and patients should continue treatment with their usual anti-hypertensive therapy and not to add or remove any RAAS-related treatments, beyond actions based on standard clinical practice ([@bb0025]; [@bb0120]).

5. Roles of intrinsic disorder in the SARS-CoV-2 -- RAAS interplay {#s0025}
==================================================================

Since it is known that viral proteomes contain noticeable levels of intrinsically disordered proteins and viral proteins utilize intrinsic disorder during host cell invasion, and since in its turn host is utilizing intrinsic disorder in fighting the viral infection, we looked at the intrinsic disorder status of viral and host proteins associated with the SARS-CoV-2 -- RAAS interplay.

5.1. Functional disorder in the spike glycoprotein from SARS-CoV-2 {#s0030}
------------------------------------------------------------------

Spike glycoprotein (S) is a large single-pass transmembrane multifunctional protein defining the exterior of the CoV particles, where it forms surface homotrimers ([@bb0050]; [@bb0245]) (see [Fig. 1](#f0005){ref-type="fig"}A) and interacts with the virion M protein via its C-terminal transmembrane region ([@bb0030]; [@bb0415]). Importantly, this structure of the S protein resolved to 3.46 Å using cryo-electron microscopy (cryo-EM) ([@bb0705]) is characterized by the absence of multiple residues (1--26, 67--78, 96--98, 143--155, 177--186, 247--260, 329--334, 444--448, 455--490, 501--502, 621--639, 673--686, 812--814, 829--851, 1147--1288). Therefore, at least 327 residues assembled into the 15 regions ranging in length from 2 to 142 residues are missing from this structure, indicating their high conformational flexibility. The longest missing region is the C-terminal region that includes a single-pass transmembrane region and an intracellular domain.Fig. 1Structure and intrinsic disorder propensity of spike glycoprotein from SARS-CoV-2. A. A 3.46 Å resolution cryo-EM structure of a homotrimeric form of spike glycoprotein from SARS-CoV-2 (PDB ID: [6VSB](pdb:6VSB){#ir0005}). B. A X-ray crystal structure (resolution of 2.45 Å) of a complex between the human ACE2 receptor (blue structure) and the RBD of the S protein from SARS-CoV-2 (red structure) (PDB ID: [6M0J](pdb:6M0J){#ir0010}). C. Intrinsic disorder profile generated for the S protein from SARS-CoV-2 by DiSpi web-crawler aggregate the results from a set of commonly used predictors of intrinsic disorder, such as PONDR® VLXT ([@bb0515]), PONDR® VL3 ([@bb0485]), PONDR® VLS2B ([@bb0480]), PONDR® FIT ([@bb0725]), IUPred2 (Short) and IUPred2 (Long) ([@bb0135], [@bb0140]). This tool enables the rapid generation of disorder profile plots for individual polypeptides as well as arrays of polypeptides.Fig. 1

The S protein consists of an N-terminal signal peptide, a long extracellular domain, a single-pass transmembrane domain, and a short intracellular domain ([@bb0030]). Functionally, S protein contains two ectodomains, S1 and S2, with specific biological roles, where binding of the subunit S1 to the host cell receptors (via the receptor-binding domain, RBD) initiates viral infection, whereas the viral entry into the host cells is mediated by the S2 subunit that acts as a class I viral fusion protein moderating the fusion of the virion and cellular membranes ([@bb0020]; [@bb0110]; [@bb0375]). [Fig. 1](#f0005){ref-type="fig"}B represents a crystal structure of a complex between the human ACE2 receptor and the RBD of the SARS-CoV-2 S protein resolved to 2.45 Å ([@bb0355]). In this structure, residues 319--332 and 527--547 (numbering corresponds to the full-length S protein) of the RBD constitute regions of missing electron density; i.e., regions with high conformational flexibility.

Although S-proteins from different CoVs typically show high level of sequence conservation at their C-terminal regions, the N-terminal regions of S proteins display noticeable differences. It was pointed out that SARS-CoV-2 appears to be optimized for binding to the ACE2 receptor. In fact, six amino acids within the RBD (which are L455, F486, Q493, S494, N501, and Y505 in SARS-CoV-2) are crucial for binding to ACE2 receptors ([@bb0010]; [@bb0665]). Five of these six residues in SARS-CoV-2 are different from the ACE2 receptor-binding residues in SARS-CoV, suggesting that this sequence variability might be the reason for the observed differences between SARS-CoV-2 and SARS-CoV in their virulence, receptor-mediated binding and entry into the host cell ([@bb0010]; [@bb0665]).

S protein is known to undergo maturation, which represents specific posttranslational modification (PTM) that involves two-step proteolytic cleavage. At the first stage, a host cell protease (e.g. furin) nicks the S precursor to generate two separate S1 and S2 subunits that remain to be joined together via a set of the non-covalent interactions. At the next stage that happened after the viral attachment to host cell receptors, S2 subunit undergoes additional cleavage by the host protease TMPRSS2, leading to the release of a fusion peptide and generation of the S2' subunit that also serves as fusion-mediating subunit ([@bb0020]; [@bb0110]). In S protein of SARS-CoV, the first and second cleavage sites are located at the residues R667 and R797, respectively. In the SARS-CoV-2 spike, which is a 1273-residue-long protein, the first cleavage site (residue R684; note that here and in the subsequent text, while discussing the functionality of different residues/regions of the SARS-CoV-2 spike protein, numbering of residues in S from SARS-CoV-2 is based on the pairwise alignment of the sequences S proteins from SARS-CoV-2 and SARS-CoV) is located in a close proximity to the C-terminus of a polybasic region introduced to this protein through the insertion of 4 residues and a series of specific mutations. In fact, in S of SARS-CoV, this cleavage site is located within the TVS\-\-\--LLRSTSQKS region, whereas in spike protein from the SARS-CoV-2, the corresponding region is TQTNSPRRARSVASQS. Altogether, this polybasic region constitutes a novel furin cleavage site of the SARS-CoV-2 spike protein ([@bb0010]), which could represent one of the reasons for the higher binding affinity of the SARS-CoV-2 S protein to ACE2 than S protein from Human SARS ([@bb0705]). The second cleavage site generating the S2' subunit in S from SARS-CoV-2 is located at residue R815. [Fig. 1](#f0005){ref-type="fig"}C represents an intrinsic disorder profile generated for the SARS-CoV-2 S protein by several commonly used disorder predictors and clearly shows that both cleavage sites associated with the spike maturation are located within the intrinsically disordered protein regions (IDPRs). This in agreement with a well-known fact that the proteolytic digestion is orders of magnitude faster in unstructured as compared to structured protein regions ([@bb0115]; [@bb0220]; [@bb0210]; [@bb0215]; [@bb0320]; [@bb0495]). Therefore, it is extremely important for the protein cleavage process that the sites of cleavage be located in regions that lack structure or possess high structural flexibility.

Furthermore, in the SARS-CoV-2 S protein, fusion peptide (residues 790--808) is located within a flexible region characterized by the mean disorder score of 0.419 ± 0.085. S protein contains two heptad repeat regions that form coiled-coil structure during viral and target cell membrane fusion, assuming a trimer-of-hairpins structure needed for the functional positioning of the fusion peptide. In human SARS-CoV-2 S protein, heptad repeat regions are formed by residues 920--970 and 1163--1202, which have mean disorder scores of 0.441 ± 0.112 and 0.353 ± 0.062, respectively. Another functional region found in S protein is the receptor-binding domain (residues 319--543) containing a receptor-binding motif (residues 440--510) responsible for interaction with human ACE2. Based on the intrinsic disorder predisposition analysis, this motif is characterized by noticeable structural flexibility with the mean disorder score of 0.29 ± 0.12 and contains a short disordered region (residues 442--445). Computational analysis (using specific algorithms, such as MoRFchibi_web ([@bb0395]), ANCHOR ([@bb0150]; [@bb0430]), MoRFPred ([@bb0125]), and DISOPRED3 ([@bb0325])) revealed that the S protein from SARS-CoV-2 contains several molecular recognition features (MoRFs), which are the short interaction-prone disordered regions located within IDPs/IDPRs that undergo a disorder-to-order transition upon binding to their partners ([@bb0070]; [@bb0300]; [@bb0440]; [@bb0455]; [@bb0640]), which are important for protein-protein interactions, and may initiate an early step in molecular recognition. In fact, SARS-CoV-2 S protein was predicted to contain three MoRFs, residues 1--10, 819--823, and 1265--1272, suggesting that intrinsic disorder could be needed for interaction of this protein with its binding partners. It is likely that the N-terminal MoRF can be engaged in the interaction of this protein with the host receptor, whereas C-terminal MoRF can be related to the S-M interaction and viral assembly. In addition to protein-binding regions, S protein is predicted to contain many RNA- and DNA-binding residues. Therefore, intrinsic disorder in the S protein is crucial for the maturation of this protein and also can be utilized in protein-protein interaction, as well as RNA and DNA binding, interaction with host cell membrane, and further viral infection.

5.2. Intrinsic disorder in renin-angiotensin-aldosterone system {#s0035}
---------------------------------------------------------------

The major RAAS components are prorenin/renin, angiotensinogen/angiotensin I/angiotensin II, angiotensin converting enzymes 1 and 2 (ACE1 and ACE2), angiotensin II receptors type 1 and type 2 (AT~1~R and AT~2~R), and MAS1 receptor. Structural side of these proteins is studied rather well.

[Fig. 2](#f0010){ref-type="fig"} represents available structures of human renin, angiotensinogen, ACE1, ACE2, as well as AT~1~R and AT~2~R. [Fig. 2](#f0010){ref-type="fig"}A shows high resolution (1.8 Å) X-ray crystal structure of the homodimeric form of human renin (PDB ID: [1HRN](pdb:1HRN){#ir0120}) ([@bb0605]). This protein (340 residues) is generated as a result of the maturation of the 406-residue-long prorenin (UniProt ID: [P00797](uniprotkb:P00797){#ir0125}) by the removal of a signal peptide (residues 1--23) and propeptide or activation peptide (residues 24--66). Mature renin, which is a highly specific endopeptidase with the only known function to generate angiotensin I from angiotensinogen, is glycosylated at positions N71 and N141 (residue numbering follows that of the prorenin) and has multiple phosphorylation sites (residues S41, S45, Y87, T330, S347, and S355). [Fig. 3](#f0015){ref-type="fig"}A and a show that prorenin is predicted to contain several disordered and flexible regions; i.e., regions with the predicted disorder scores exceeding 0.5 and falling within the 0.2--0.5 range, respectively. Proteolytic sites used for the removal of signal peptide and propeptide, as well as glycosylation and phosphorylation sites are located within or in close proximity to the flexible or disordered regions (see [Fig. 3](#f0015){ref-type="fig"}A and a), indicating that intrinsic disorder and structural flexibility found in proreinin/renin are functionally important.Fig. 2Structural characterization of the renin-angiotensin-aldosterone system members. A. High resolution (1.8 Å) X-ray crystal structure of human renin (PDB ID: [1HRN](pdb:1HRN){#ir0015}) ([@bb0605]). B. X-ray crystal structure of human angiotensinogen (PDB ID: [2WXW](pdb:2WXW){#ir0020}) ([@bb0770]). C. Overlaid crystal structures of the peptidase M2 1 domain (N-domain, residues 30--658; PDB ID: [3NXQ](pdb:3NXQ){#ir0025}:A ([@bb0015])) and the peptidase M2 2 domain (C-domain, residues 642--1232; PDB ID: [2IUL](pdb:2IUL){#ir0030}; ([@bb0690])) shown by red and blue colors, respectively. Multiple structure alignment was conducted using the MultiProt algorithm ([@bb0540]), and VMD platform was used to generate this image ([@bb0310]). D. Crystal structure of angiotensin II type 1 receptor (AT~1~R, blue chain) bound to the angiotensin-like peptideS1I8 (red chain) and stabilized by the nanobody (cyan and yellow chains) (PDB ID: ([@bb0700])). E, crystal structure of the chimera protein of human AT1R and soluble cytochrome *b*~*562*~ from *Escherichia coli* (PDB ID: [5UNG](pdb:5UNG){#ir0035}; ([@bb0760])).Fig. 2Fig. 3Disorder profiles generated for the members of human RAAS by the D^2^P^2^ computational platform (plots A, B, C, D, E, F, and G) and by the DiSpi web-crawler (plots a, b, c, d, e, f, and g). A, a. Prorenin (UniProt ID: [P00797](uniprotkb:P00797){#ir0040}); B, b. Angiotensinogen (UniProt ID: [P01019](uniprotkb:P01019){#ir0045}); C, c. Angiotensin-converting enzyme 1 (UniProt ID: [P12821](uniprotkb:P12821){#ir0050}); D, d. Angiotensin-converting enzyme 2 (UniProt ID: [Q9BYF1](uniprotkb:Q9BYF1){#ir0055}); E, e. Type-1 angiotensin II receptor (UniProt ID: [P30556](uniprotkb:P30556){#ir0060}); F, f. Type-2 angiotensin II receptor (UniProt ID: [P50052](uniprotkb:P50052){#ir0065}); G, g. Proto-oncogene Mas (MAS1; UniProt ID: [P04201](uniprotkb:P04201){#ir0070}).Fig. 3

[Fig. 2](#f0010){ref-type="fig"}B represents X-ray crystal structure of mature human angiotensinogen (PDB ID: [2WXW](pdb:2WXW){#ir0130}) ([@bb0770]), which is a 452-residue-long protein generated by the removal of signal peptide (residues 1--33) from a precursor protein (485 residues UniProt ID: [P01019](uniprotkb:P01019){#ir0135}). There are two regions of missing electron density in this protein, residues 404--415 and 450--452. Mature angiotensinogen is further processed by cellular proteases to generate a series of peptide hormones with the decreasing length, such as angiotensin I (residues 34--43), angiotensin-(1--9) (residues 34--42), angiotensin II (residues 34--41), angiotensin-(1--7) (residues 34--39), angiotensin-(1--5) (residues 34--38), angiotensin-(1--4) (residues 34--37), angiotensin III (residues 35--41), and angiotensin IV (residues 36--41). [Fig. 3](#f0015){ref-type="fig"}B and b represent disorder profiles of human angiotensinogen and show that the aforementioned sites associated with the maturation and processing of this protein and regions of missing electron density are located within the disordered or flexible regions. NMR solution structure of the angiotensin I (PDB ID: [1N9U](pdb:1N9U){#ir0140}) is shown in [Fig. 4](#f0020){ref-type="fig"} ([@bb0585]), which illustrates that this peptide exists in an extended conformation in solution.Fig. 4NMR solution structure of the angiotensin I (PDB ID: [1N9U](pdb:1N9U){#ir0075}; ([@bb0585])).Fig. 4

Metalloprotease ACE1 is a multifunctional enzyme that, in addition to being dipeptidyl carboxypeptidase that hydrolyses peptides by the removal of a dipeptide from the C-terminus, thereby converting the hormone angiotensin I to the active vasoconstrictor angiotensin II ([@bb0085]), also plays a role in degradation of bradykinin and amyloid β-protein ([@bb0280]) and shows some glycosidase activity cleaving the mannose linkage in the glycosylphosphatidylinositol (GPI)-anchored proteins. In somatic tissues, ACE1 represents a translated tandem duplication that produces a protein with two functional domains, the N-terminal peptidase M2 1 domain (residues 30--630) and the C-terminal peptidase M2 2 domain (residues 631--1232). ACE1 is a type 1 C-terminally membrane anchored ectoenzyme, with the hydrophobic transmembrane anchor included in the C-terminal most part of the protein ([@bb0085]). Human ACE1 undergoes posttranslational processing causing the removal of the N-terminally located signaling peptide (residues 1--29) and, to generate a soluble form, C-terminally located propeptide that serves as the aforementioned hydrophobic transmembrane anchor (residues 1233--1306). Structural information is available for most parts of the soluble form this protein. [Fig. 2](#f0010){ref-type="fig"}C represents overlaid crystal structures of the peptidase M2 1 (residues 30--658; PDB ID: [3NXQ](pdb:3NXQ){#ir0145}:A; ([@bb0015])) and peptidase M2 2 domains (residues 642--1232; PDB ID: [2IUL](pdb:2IUL){#ir0150}; ([@bb0690])) shown by red and blue colors, respectively. It is clearly seen that the N- and C-domains of human AC1 are almost identical structurally (in fact, 577 residues of both domains were included in this structural alignment that is characterized by the RMSD of 0.99 Å). In these structures, residues 159--161 and 640--658 in peptidase M2 1 are missing. These regions, together with signaling peptide and a loop connecting transmembrane anchor with the soluble ACE1 are predicted to be disordered/flexible (see [Fig. 3](#f0015){ref-type="fig"}C and c). Furthermore, this protein contains several PTM sites, and its N-terminal region is predicted to possess a MoRF (residues 14--22) (see [Fig. 3](#f0015){ref-type="fig"}D).

Carboxypeptidase ACE2 converts angiotensin I to angiotensin-(1--9) and angiotensin II to angiotensin-(1--7) ([@bb0130]; [@bb0595]; [@bb0650]), hydrolyzes biologically active peptides apelin-13 and dynorphin-13 ([@bb0650]), interacts, in intestine, with the amino acid transporter SL6A19 and regulates its catalytic activity ([@bb0040]; [@bb0335]), and serves as a receptor for SARS-CoV-2, SARS-CoV, and human CoV-NL63, interacting with their spike proteins ([@bb0290]; [@bb0295]; [@bb0370]; [@bb0705]). As it was already pointed out, a crystal structure of a complex between the ACE2 receptor (residues 1--615) and the RBD of the S protein from SARS-CoV-2 was recently solved ([@bb0355]) (see [Fig. 1](#f0005){ref-type="fig"}B). In this and other structures of ACE2, N-terminal residues 1--18 constitute a region of missing electron density. Furthermore, no structural information is available for the C-terminal region of this protein (residues 616--805). Maturation of human ACE2 involves the removal of a signal peptide (residues 1--17). Also, this protein can be further processed via the removal of C-terminal residues 709--805. Several ACE2 residues are N-glycosylated (N53, N59, N103, N322, N432, N546, and N690). [Fig. 3](#f0015){ref-type="fig"}D and d indicate that the N- and C-terminal regions of human ACE2 contain noticeable levels of intrinsically disordered or flexible residues, and glycosylation sites are preferentially located within disordered or flexible regions (see [Fig. 3](#f0015){ref-type="fig"}D).

Angiotensin II type 1 receptor (AT~1~R) is a prototypical G-protein-coupled receptor (GPCR) that serves as a critical regulator of cardiovascular and renal function ([@bb0330]; [@bb0700]). GPCRs are the largest family of transmembrane proteins in humans, acting as cricial regulators of almost every aspect of human physiology. AT~1~R is one of the key members of the RAAS, promoting a wide range of intracellular signaling pathways resulting in endothelial dysfunction, hypertension, end organ damage, and vascular remodeling ([@bb0330]). AT~1~R-mediated signaling represents a complex set of signaling pathways that include G protein-dependent signaling, G protein-independent signaling, NADPH oxidase and ROS signaling, transactivation of growth factor receptors, β-arrestin-mediated signaling, signaling pathways initiated by several AT~1~R interacting proteins, as well as a functional cross-talk between the AT~1~R signaling pathway and other signaling pathways ([@bb0330]). [Fig. 2](#f0010){ref-type="fig"}D represents a crystal structure of AT~1~R (blue chain) bound to the angiotensin-like peptide S1I8 (red chain) and stabilized by the nanobody (cyan and yellow chains) (PDB ID: [6DO1](pdb:6DO1){#ir0155}) and shows that the AT~1~R structure is typical for seven-transmembrane receptors ([@bb0700]). [Fig. 2](#f0010){ref-type="fig"}E illustrates that the angiotensin II type 2 receptor (AT~2~R) shows very similar structural organization possessing seven transmembrane α-helices characteristic for the GPCR family (PDB ID: [5UNG](pdb:5UNG){#ir0160}; ([@bb0760])). [Fig. 3](#f0015){ref-type="fig"}E, e, F, and f show that in line with this high structural similarity, AT~1~R and AT~2~R have rather similar disorder profiles, which are characterized by the disordered N- and C-terminal regions and the presence of several flexible regions dispersed within the rather ordered backbone. These receptors also contain several PTM sites embedded within the IDPRs (see [Fig. 3](#f0015){ref-type="fig"}E and F). Similar to other members of the GPCR family ([@bb0205]), cytoplasmic C-tails represent the most disordered regions of the AT~1~R and AT~2~R. Although no structural information is currently available for the MAS1 receptor, it is likely that this GPCR is structurally similar to AT~1~R and AT~2~R. This conclusion is supported by [Fig. 3](#f0015){ref-type="fig"}G and g showing remarkable similarity of the disorder profile generated for human MAS1 with the disorder profiles of AT~1~R and AT~2~R.

Since binding promiscuity represents one of the important functional features of IDPs/IDPRs ([@bb0175]; [@bb0450]; [@bb0615], [@bb0620], [@bb0625]; [@bb0635]), we analyzed interactivity of human RAAS proteins. IDPs and hybrid proteins containing ordered domains and IDRs are considered as binding "professionals", which are always engaged in interactions with different partners utilizing multiple binding modes ([@bb0175]; [@bb0450]; [@bb0625]; [@bb0635]). IDPs/IDPRs can form static, semi-static, and dynamic complexes ([@bb0615], [@bb0620]), participate in polyvalent interactions ([@bb0400]; [@bb0630]), and fold at binding to their partners ([@bb0180]; [@bb0185]; [@bb0710]). Since degrees of such binding-induced folding can vary in a wide range, the resulting complexes show wide structural and functional heterogeneity ([@bb0615], [@bb0620]). Some IDPs/IDPRs fold differently at binding to different partners ([@bb0095]; [@bb0190]; [@bb0170]; [@bb0195]; [@bb0300]; [@bb0340]; [@bb0420]; [@bb0450]; [@bb0460]; [@bb0610]; [@bb0710]), whereas other IDPs/IDPRs form fuzzy complexes, where significant levels of disorder are preserved at least outside the binding interface ([@bb0225]; [@bb0230]; [@bb0275]; [@bb0490]; [@bb0535]; [@bb0555]; [@bb0560]; [@bb0600]). Since disorder-based interactions are often characterized by high specificity and low affinity, IDPs/IDPRs are suited well for signaling functions ([@bb0530]). Finally, many IDPs/IDPRs have highly connected central positions in complex protein-protein interaction (PPI) networks, acting as hubs ([@bb0145]; [@bb0190]; [@bb0200]; [@bb0270]; [@bb0470]; [@bb0570]; [@bb0575]). For evaluation of interactivity of the RAAS proteins, we utilized Search Tool for the Retrieval of Interacting Genes (STRING, <http://string-db.org/>) ([@bb0590]). [Fig. 5](#f0025){ref-type="fig"}A shows the inter-RAAS PPI network generated by STRING at the high confidence level of 0.7 and demonstrates that these seven proteins form a highly interconnected network with an average node degree of 4.29. Next, we looked at the global interactivity of the whole set of human RAAS proteins by including a first shell interactors (i.e., proteins interacting with RAAS proteins). The resulting network is shown in [Fig. 5](#f0025){ref-type="fig"}B. This RAAS-centered PPI network that was built using custom confidence level of 0.901 contains 394 nodes (proteins) connected by 20,014 edges (PPIs). In this network, the average node degree is 102, and its average local clustering coefficient (which defines how close its neighbors are to being a complete clique; the local clustering coefficient is equal to 1 if every neighbor connected to a given node Ni is also connected to every other node within the neighborhood, and it is equal to 0 if no node that is connected to a given node Ni connects to any other node that is connected to Ni) is 0.713. Since the expected number of interactions among proteins in a similarly sized set of proteins randomly selected from human proteome is equal to 3227, this RAAS-centered PPI network has significantly more interactions than expected, being characterized by a PPI enrichment *p*-value of \<10^−16^. Therefore, these data indicate that human RAAS proteins are promiscuous binders that form a dense PPI network. It is likely that at least in part this high interactivity of the RAAS proteins can be related to their IDPRs.Fig. 5Analysis of the internal (A) and external (B) interactability of the RAAS members conducted by Search Tool for the Retrieval of Interacting Genes (STRING, <http://string-db.org/>) that generates a network of predicted associations based on predicted and experimentally-validated information on the interaction partners of a protein of interest ([@bb0590]). In the corresponding network, the nodes correspond to proteins, whereas the edges show predicted or known functional associations. Seven types of evidence are used to build the corresponding network, where they are indicated by the differently colored lines: a green line represents neighborhood evidence; a red line - the presence of fusion evidence; a purple line - experimental evidence; a blue line -- co-occurrence evidence; a light blue line - database evidence; a yellow line -- text mining evidence; and a black line -- co-expression evidence ([@bb0590]).Fig. 5

5.3. Intrinsic disorder in transmembrane protease, serine 2 (TMPRSS2) {#s0040}
---------------------------------------------------------------------

Another important player related to the entry of SARS-CoV-2 to host cells is the cellular serine protease TMPRSS2, which is responsible for priming of S protein ([@bb0290]). S protein priming by cellular proteases is crucial for viral entry into target cells, since it leads to the cleavage of S protein at the S1/S2 and the S2' site and allows fusion of viral and cellular membranes via a process driven by the S2 subunit ([@bb0020]; [@bb0110]). In addition to priming of coronavirus spike glycoprotein that activates it for cathepsin L-independent host cell entry, TMPRSS2 might further promote viral uptake by the ACE2 cleavage ([@bb0285]). It was shown that SARS-CoV-2 receptor ACE2 and TMPRSS2 are primarily expressed in bronchial transient secretory cells ([@bb0385]). TMPRSS2 proteolytically cleaves and activates the fusion glycoproteins F0 of Sendai virus (SeV), human metapneumovirus (HMPV), and human parainfluenza 1, 2, 3, 4a and 4b viruses (HPIV). Furthermore, TMPRSS2 is involved in activation of various influenza viruses, including avian influenza viruses, such as 2013 Asian H7N9 influenza virus, by cleaving the precursor of their surface glycoprotein haemagglutinin (HA) ([@bb0545]). Since it also plays a crucial role in the proteolytic activation of SARS-CoV and MERS-CoV ([@bb0545]), TMPRSS2 is considered as a suitable target for treatment of influenza virus and coronavirus infections ([@bb0360]; [@bb0435]; [@bb0500]; [@bb0545]; [@bb0550]; [@bb0565]).

TMPRSS2 is anchored to the plasma membrane and belongs to the family of type II transmembrane serine proteases (TTSPs) ([@bb0715]). TMPRSS2 has a short intracellular N-terminal domain (residues 1--84), a transmembrane α-helical domain acting as signal-anchor (residues 85--105) and a large extracellular domain (residues 106--492) containing low-density lipoprotein (LDL) receptor class A (LDLRA, residues 112--149) that forms a binding site for LDL and calcium, scavenger receptor cysteine-rich (SRCR) domain (residues 150--242) and C-terminal serine protease domain of the chymotrypsin S1 fold (residues 256--489). Activation of TMPRSS2 involves an autocatalytic cleavage between R255 and I256 ([@bb0005]), generating non-catalytic and catalytic chains (residues 1--255 and 256--492, respectively). Although after cleavage, the mature TMPRSS2 remains mostly membrane-bound, some number of catalytic chains can be liberated into the extracellular milieu. For example, secreted forms of TMPRSS2 were found in human seminal prostasomes, suggesting the roles of this serine protease in regulation of the sperm function ([@bb0055]).

No structural information is available for human TMPRSS2. [Fig. 6](#f0030){ref-type="fig"}A and B provide an explanation for this fact showing that TMPRSS2 is expected to contain noticeable levels of intrinsic disorder. In fact, first 70 residues of this protein are predicted to be disordered. Curiously, in addition to the canonical form, TMPRSS2 has an alternatively spliced isoform 2, where M1 is substituted by MPPAPPGGESGCEERGAAGHIEHSRYLSLLDAVDNSKM. This change adds 37 disordered residues and a MoRF (residues 15--38).Fig. 6Intrinsic disorder and interactability of human transmembrane protease TMPRSS2 (UniProt ID: [O15393](uniprotkb:O15393){#ir0085}). A. Disorder profile generated by the DiSpi web-crawler. B. Functional disorder profile generated by the D^2^P^2^ computational platform. C. TMPRSS2-centered PPI network generated by STRING (<http://string-db.org/>).Fig. 6

Besides activation of multiple viruses, TMPRSS2 has a number of other biological roles. For example, it activates a proteolytic cascade involving components of the tumor microenvironment and promotes prostate cancer metastasis ([@bb0380]). In its membrane-anchored form, TMPRSS2 also activates a member of the G-protein-coupled receptors, protease-activated receptor-2 (PAR-2), in prostate cancer cells ([@bb0695]). More generally, perturbations in the regulation of expression of this surface-anchored serine protease and/or distortions in its enzymatic activity serve as contributing factors to the pathogenesis of several cancer types ([@bb0410]). To see if this multifunctionality of TMPRSS2 is linked to the binding promiscuity of this protein, we looked at its interactability using STRING platform. [Fig. 6](#f0030){ref-type="fig"}C represents TMPRSS2-centered PPI network generated utilizing medium confidence level of 0.4. This network includes 79 proteins connected by 533 interactions, while the expected number of interactions in a random similar size set of proteins is 219. The average node degree of this network is 13.6, the average local clustering coefficient is 0.713, and PPI enrichment *p*-value is \<10^−16^. It is likely that at least in part this high interactivity of TMPRSS2 can be related to its IDPRs. This information definitely needs to be taken into account while developing drugs targeting TMPRSS2 for treatment of influenza virus and coronavirus infections, since current strategies, which are most frequently used here are primarily focused on finding various serine protease inhibitors; i.e., drugs targeting the catalytic site of TMPRSS2 ([@bb0545]). However, since none of the compounds or proteins currently used for inhibition of TMPRSS2 was specifically designed to exclusively target TMPRSS2, all these inhibitors are rather non-specific and may cause unpredictable and deleterious side effects ([@bb0545]).

6. Concluding remarks {#s0045}
=====================

Assuming that an interplay between the renin-angiotensin-aldosterone system and spike glycoprotein from SARS-CoV-2 contributes to the COVID-19 pathogenesis, one should carefully analyze all the related players. Traditionally, finding potential drug leads involves rational drug design approaches based on the study of the structures and functions of target molecules. Although solving crystal structures of SARS-CoV-2 proteins, RAAS members, and complexes between the viral and human proteins undoubtedly represent important stages for future successes in finding potential anti-COVID-19 drugs, this structural biology side of the potential association of COVID-19 with RAAS should be complemented by careful and diligent investigation of the intrinsic disorder predisposition of corresponding viral and human proteins. This is especially important in light of the common practice of elimination of protein regions that resist crystallization (i.e., segments with high conformational flexibility or IDPRs). If disorder does play a role in the functionality of query proteins and is somehow related to the pathogenesis of COVID-19, then consideration of the intrinsic disorder phenomenon should be added to the modern arsenal of means for drug development. Therefore, this work represents an important step for better understanding the prevalence and functionality of intrinsic disorder in spike glycoprotein from SARS-CoV-2 and in proteins from the human renin-angiotensin-aldosterone system.
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